Literature DB >> 33280002

A Case Study of Dual Infection of Dengue and COVID-19: Presenting as Multiorgan Dysfunction in an Infant.

Maha Ashraf Kazi1, Sanajit Ghosh1, Satyabrata Roychowdhury1, Prabhas Prasun Giri2, Mihir Sarkar1.   

Abstract

Dengue is a major health concern in South Asian countries transmitted by bite of day breeder mosquitoes Aedes aegypti and Aedes albopictus. Severity of plasma leak, shock, bleeding tendency and other organ dysfunction can be more pronounced in infants. The management becomes further complicated in the presence of a co-existing COVID-19 infection. Although COVID-19 infection is usually asymptomatic or has mild manifestations in children, however in presence of serious co-infection like dengue it can modify the course of the illness and lead to drastic consequences. Here, we present one such case of a 9-month-old female child who tested positive for dengue as well as COVID-19 during the ongoing corona pandemic and went on to develop shock, encephalopathy with deranged liver enzymes but managed to overcome all odds and recover from the disease by day 14 of illness.
© The Author(s) [2020]. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  COVID-19; co-infection; infant; severe dengue

Year:  2020        PMID: 33280002     DOI: 10.1093/tropej/fmaa080

Source DB:  PubMed          Journal:  J Trop Pediatr        ISSN: 0142-6338            Impact factor:   1.165


  2 in total

1.  Multisystem Inflammatory Syndrome in a Child with Scrub Typhus and Macrophage Activation Syndrome.

Authors:  Aman Gupta; Arpinder Gill
Journal:  J Trop Pediatr       Date:  2021-01-29       Impact factor: 1.165

Review 2.  SARS-CoV-2 and dengue virus co-infection: Epidemiology, pathogenesis, diagnosis, treatment, and management.

Authors:  Chowdhury Nusaiba Binte Sayed Prapty; Raad Rahmat; Yusha Araf; Samiha Kamal Shounak; Tanjim Ishraq Rahaman; Mohammad Jakir Hosen; Chunfu Zheng; Md Golzar Hossain
Journal:  Rev Med Virol       Date:  2022-03-03       Impact factor: 11.043

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.